Decompression surgery for treating nerve damage in leprosy

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2008, Pages

  Van Veen, Natasja H J ^a   Schreuders, T A R ^b   Theuvenet, W J ^b   Agrawal, A ^b   Richardus, J H ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE;

CATARACT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DECOMPRESSION SURGERY; DISEASE SEVERITY; HUMAN; LEPROSY; NERVE FUNCTION; NERVE INJURY; NEUROLYSIS; PEPTIC ULCER; PSYCHOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

EID: 44949147223     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006983     Document Type: Review

References (44)

1. Becx-Bleumink 1990 Becx-Bleumink M, Berhe D, Mannetje W. The management of nerve damage in the leprosy control services. Leprosy Review 1990;61(1):1-11.
2. Boucher 1999 Boucher P, Millan J, Parent M, Moulia-Pela JP. Randomized controlled trial of medical and medico-surgical treatment of Hansen's neuritis [Essai compare randomise du traitement medical et medicochirurgical des nevrites hanseniennes]. Acta Leprologica 1999;11(4):171-7.
3. Bourrel 1981 Bourrel P, Giraudeau P. Direct surgery of leprous neuritis [Chirurgie directe de la nevrite lepreuse]. Acta Leprologica 1981;84:63-8.
4. Bourrel 1992 Bourrel P. Preliminary recommendations on the use of surgery for the treatment of leprosy neuritis: caution concerning the use of surgery in prevention of deformities. ILEP Technical Bulletin 1992, issue 4.
5. Brandsma 1981 Brandsma W. Basic nerve function assessment in leprosy patients. Leprosy Review 1981;52(2):161-70.
6. Brandsma 1983 Brandsma JW, Nugteren WA, Andersen JB, Naafs B. Functional changes of the ulnar nerve in leprosy patients following neurolysis. Leprosy Review 1983;54(1):31-8.
7. Britton 1998 Britton WJ. The management of leprosy reversal reactions. Leprosy Review 1998;69(3):225-34.
8. Carayon 1993 Carayon A, van Droogenbroeck J, Courbil J, Boucher P, Naafs N. Treatment of leprotic neuritis. Exclusive medical treatment or combined with decompression [Evolution du traitement des nevrites hanseniennes. Traitement medical exclusif ou associe a la decompression]. Medecine Tropicale 1993;53(4):493-504.
9. Croft 1999 Croft RP, Richardus JH, Nicholls PG, Smith WC. Nerve function impairment in leprosy: design, methodology, and intake status of a prospective cohort study of 2664 new leprosy cases in Bangladesh (The Bangladesh Acute Nerve Damage Study). Leprosy Review 1999;70(2):140-59.
10. Croft 2000 Croft RP, Nicholls PG, Richardus JH, Smith WC. The treatment of acute nerve function impairment in leprosy: results froma prospective cohort study in Bangladesh. Leprosy Review 2000;71(2):154-68.
11. Dandapat 1991 Dandapat MC, Sahu DM, Mukherjee LM, Panda C, Baliarsing AS. Treatment of leprous neuritis by neurolysis combined with perineural corticosteroid injection. Leprosy Review 1991;62(1):27- 34.
12. Droogenbroeck 1977 Van Droogenbroeck JBA, Naafs B. Surgical nerve release in leprosy: a study with comparison with non operated opposite nerves [Etude comparative d'une serie de nerfs lepreux decomprimes chirurgicalement par rapport aux nerfs controlateraux non operes]. Medecine Tropicale 1977;37(6):771-6.
13. Ebenezer 1996 Ebenezer M, Andrews P, Solomon S. Comparative trial of steroids and surgical intervention in the management of ulnar neuritis. International Journal of Leprosy and Other Mycobacterial Diseases 1996;64(3):282-6.
14. Heijnders 2004 Heijnders ML. The dynamics of stigma in leprosy. International Journal of Leprosy and Other Mycobacterial Diseases 2004;72(4):437-47.
15. Higgins 2005 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Interventions 4.2.5 [updated May 2005]. The Cochrane Library, Issue 3. Chichester, UK: John Wiley & Sons, Ltd, 2005.
16. ILEP 2001 The International Federation of Anti-Leprosy Associations (ILEP). How to diagnose and treat leprosy. London: ILEP, 2001.
17. ILEP 2002 The International Federation of Anti-Leprosy Associations (ILEP). How to recognise and manage reactions. London: ILEP, 2002.
18. Job 1989 Job CK. Nerve damage in leprosy. International Journal of Leprosy and Other Mycobacterial Diseases 1989;57(2):532-9.
19. Juni 2001 Juni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42-6.
20. Leekassa 2004 Leekassa R, Bizuneh E, Alem A. Prevalence of mental distress in the outpatient clinic of a specialized leprosy hospital. Addis Ababa, Ethiopia, 2002. Leprosy Review 2004;75(4):367-75.
21. Lockwood 1993 Lockwood DN, Vinayakumar S, Stanley JN, McAdam KP, Colston MJ. Clinical features and outcome of reversal (type 1) reactions in Hyderabad, India. International Journal of Leprosy and Other Mycobacterial Diseases 1993;61(1):8-15.
22. Lockwood 2000 Lockwood DN. Steroids in leprosy type 1 (reversal) reactions: mechanisms of action and effectiveness. Leprosy Review 2000;71(Supplement):S111-4.
23. Lockwood 2005 Lockwood DN, Suneetha S. Leprosy: too complex a disease for a simple elimination paradigm. Bulletin of the World Health Organization 2005;83(3):230-5.
24. Marlowe 2004 Marlowe SN, Hawksworth RA, Butlin CR, Nicholls PG, Lockwood DN. Clinical outcomes in a randomized controlled study comparing azathioprine and prednisolone versus prednisolone alone in the treatment of severe leprosy type 1 reactions in Nepal. Transactions of the Royal Society of Tropical Medicine and Hygiene 2004;98(10):602-9.
25. Naafs 1996 Naafs B. Treatment of reactions and nerve damage. International Journal of Leprosy and Other Mycobacterial Diseases 1996;64(4 Supplement):S21-8.
26. Nicholls 2003 Nicholls PG, Croft RP, Richardus, JH, Withington SG, Smith WC. Delay in presentation, an indicator for nerve function status at registration and for treatment outcome - the experience of the Bangladesh Acute Nerve Damage Study cohort. Leprosy Review 2003;74(4):349-56.
27. Pannikar 1984 Pannikar VK, Ramprasad S, Reddy NR, Andrews P, Ravi K, Fritschi EP. Effect of epicondylectomy in early ulnar neuritis treated with steroids. International Journal of Leprosy and Other Mycobacterial Diseases 1984;52(4):501-5.
28. Pearson 1982 Pearson JM. The evaluation of nerve damage in leprosy. Leprosy Review 1982;53(2):119-30.
29. Rafferty 2005 Rafferty J. Curing the stigma of leprosy. Leprosy Review 2005;76(2):119-26.
30. Rao 1989 Rao KS, Siddalinga Swamy MK. Sensory recovery in the plantar aspect of the foot after surgical decompression of posterior tibial nerve. Possible role of steroids along with decompression. Leprosy Review 1989;60(4):283-7.
31. Richard 2004 Richard B. Surgical management of neuritis. In: SchwarzR, BrandsmaW editor(s). Surgical reconstruction & rehabilitation in leprosy and other neuropathies. Kathmandu, Nepal: Ekta Books, 2004.
32. Richardus 2003 Richardus JH, Withington SG, Anderson AM, Croft RP, Nicholls PG, Van Brakel WH, et al.Adverse events of standardized regimens of corticosteroids for prophylaxis and treatment of nerve function impairment in leprosy: results from the 'TRIPOD' trials. Leprosy Review 2003;74(4):319-27.
33. Ridley 1966 Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five-group system. International Journal of Leprosy and Other Mycobacterial Diseases 1966;34(3):255-73.
34. Saunderson 2000 Saunderson P, Gebre S, Desta K, Byass P, Lockwood DN. The pattern of leprosy-related neuropathy in the AMFES patients in Ethiopia: definitions, incidence, risk factors and outcome. Leprosy Review 2000;71(3):285-308.
35. Schreuder 1998 Schreuder PA. The occurrence of reactions and impairments in leprosy: experience in the leprosy control program of three provinces in northeastern Thailand, 1987-1995 [correction of 1978-1995]. III. Neural and other impairments. International Journal of Leprosy and Other Mycobacterial Diseases 1998;66(2):170-81.
36. Sena 2006 Sena CB, Salgado CG, Tavares CM, Da Cruz CA, Xavier MB, Do Nascimento JL. Cyclosporine A treatment of leprosy patients with chronic neuritis is associated with pain control and reduction in antibodies against nerve growth factor. Leprosy Review 2006;77(2):121-9.
37. Sugumaran 1998 Sugumaran DS. Leprosy reactions - complications of steroid therapy. International Journal of Leprosy and Other Mycobacterial Diseases 1998;66(1):10-5.
38. Van Brakel 2003 Van Brakel WH, Anderson AM, Withington SG, Croft RP, Nicholls PG, Richardus JH, et al.The prognostic importance of detecting mild sensory impairment in leprosy: a randomized controlled trial (TRIPOD 2). Leprosy Review 2003;74(4):300-10.
39. Van Brakel 2005 van Brakel WH, Nicholls PG, Das L, Barkataki P, Suneetha SK, Jadhav RS, et al.The INFIR Cohort Study: investigating prediction, detection and pathogenesis of neuropathy and reactions in leprosy. Methods and baseline results of a cohort of multibacillary leprosy patients in north India. Leprosy Review 2005;76(3):14-34.
40. Van Veen 2007 Van Veen NH, Nicholls PG, Smith WC, Richardus JH. Corticosteroids for treating nerve damage in leprosy. Cochrane Database of Systematic Reviews 2007, Issue 2.Art. No.: CD005491. DOI: 10.1002/14651858.CD005491.pub2.[MEDLINE: CD005491].
41. WHO 1998 World Health Organization. WHO Expert Committee on Leprosy [editorial]. World Health Organization Technical Report Series 1998;874:1-43.
42. WHO 2004 World Health Organization. WHO Leprosy Elimination Project: Status Report 2003, draft. http://www.searo.who.int/LinkFiles/ Leprosy_s20042.pdf 2004.
43. WHO 2006a World Health Organization. Leprosy. http://www.who.int/ mediacentre/factsheets/fs101/en/index.html (Accessed 26 June 2007).
44. WHO 2006b World Health Organization. Global leprosy situation, 2006. Weekly Epidemiological Record 2006;81(32):309-16.